H

Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627

Watchlist Manager
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Watchlist
Price: 4.99 CNY 4.61% Market Closed
Market Cap: 24.7B CNY
Have any thoughts about
Hubei Biocause Pharmaceutical Co Ltd?
Write Note

Hubei Biocause Pharmaceutical Co Ltd
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hubei Biocause Pharmaceutical Co Ltd
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Minority Interest
ÂĄ12.9B
CAGR 3-Years
-4%
CAGR 5-Years
0%
CAGR 10-Years
78%
China Life Insurance Co Ltd
SSE:601628
Minority Interest
ÂĄ10.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
16%
Ping An Insurance Group Co of China Ltd
SSE:601318
Minority Interest
ÂĄ333.7B
CAGR 3-Years
9%
CAGR 5-Years
17%
CAGR 10-Years
18%
New China Life Insurance Company Ltd
SSE:601336
Minority Interest
ÂĄ28m
CAGR 3-Years
21%
CAGR 5-Years
23%
CAGR 10-Years
19%
S
Sunshine Insurance Group Co Ltd
HKEX:6963
Minority Interest
ÂĄ1.3B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Biocause Pharmaceutical Co Ltd
Glance View

Market Cap
24.7B CNY
Industry
Insurance

Hubei Biocause Pharmaceutical Co., Ltd began its journey in the health sector by positioning itself strategically in the pharmaceutical industry. With its headquarters set in the Hubei Province of China, this company has intricately woven itself into the fabric of modern healthcare. Primarily, it thrives by developing, manufacturing, and distributing a variety of pharmaceutical products including both traditional and modern-medicine drugs. The journey of Biocause is punctuated by its research-driven approach, which focuses on innovation and quality control across its production lines, ensuring it stays at the forefront of pharmaceutical advancements. Revenue generation for Hubei Biocause predominantly comes from the sale of medications and healthcare products, but the company's financial tapestry is more diversified. It has explored opportunities by extending its business horizon beyond pharmaceuticals, tapping into other ventures such as insurance services. This diversification has enabled Biocause to stabilize its financial structure and mitigate risk, leveraging its steady pharma income to branch into realms that complement its healthcare base. Alongside, their strategic partnerships and alliances further bolster their market position, allowing for a broadened geographical reach and a more substantial impact on the sectors they operate within. Thus, Hubei Biocause crafts a story not only of pharmaceutical excellence but of strategic breadth that spawns wider market opportunities.

Intrinsic Value
4.6 CNY
Overvaluation 8%
Intrinsic Value
Price
H

See Also

What is Hubei Biocause Pharmaceutical Co Ltd's Minority Interest?
Minority Interest
12.9B CNY

Based on the financial report for Sep 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Minority Interest amounts to 12.9B CNY.

What is Hubei Biocause Pharmaceutical Co Ltd's Minority Interest growth rate?
Minority Interest CAGR 10Y
78%

Over the last year, the Minority Interest growth was -1%. The average annual Minority Interest growth rates for Hubei Biocause Pharmaceutical Co Ltd have been -4% over the past three years , and 78% over the past ten years .

Back to Top